Paper Details

  1. Home
  2. Paper Details

Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6.

Author: AbbaszadehSaber, Asadi-SamaniMajid, Ashrafi-DehkordiKorosh, BasatiGholam, Saffari-ChaleshtoriJavad

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the molecular dynamic effects of abemaciclib, hymenialdisine, and indirubin on the structure of CDK-6. The study found that CDK-6 is inhibited via high binding affinity to the three inhibitors, and induces variation in the secondary structure and Rg in CDK-6 docked to the inhibitors.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Cyclin-Dependent Kinases-6 (CDK-6) is a serine/threonine protein kinase with regular activity in the cell cycle. Some inhibitors, such as abemaciclib, hymenialdisine, and indirubin, cause cell arrest by decreasing its activity. OBJECTIVES: The purpose of this study was to evaluate the M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/2589977511666191018180001

データ提供：米国国立医学図書館（NLM）

CDK-6: A Desert Oasis of Cancer Treatment

Cancer treatment is a challenging journey, with researchers constantly seeking new oases of effective therapies. This research explores the molecular mechanisms by which three inhibitors, abemaciclib, hymenialdisine, and indirubin, inhibit CDK-6, a key enzyme involved in cell cycle regulation. The study’s findings suggest that these inhibitors bind to CDK-6 and induce changes in its structure, potentially leading to cell arrest and cancer cell death.

CDK-6 Inhibitors: A New Oasis in the Desert of Cancer Treatment

The study’s findings, like a shimmering oasis in the desert of cancer treatment, offer a potential new path to combatting this devastating disease. The researchers’ observations regarding the binding of these inhibitors to CDK-6 and the subsequent structural changes provide valuable insights into the mechanisms of cancer cell growth and the potential for targeted therapies.

Cancer Treatment: A Journey Through a Desert of Challenges

Cancer treatment, like a relentless desert heat, can be a grueling and challenging experience. This research underscores the need for ongoing research to develop effective and safe treatment options for this condition. The study’s findings offer a glimmer of hope, but further research is crucial to fully understand the potential of these inhibitors and optimize their use in cancer treatment.

Dr.Camel's Conclusion

This study explores the molecular mechanisms of three inhibitors, abemaciclib, hymenialdisine, and indirubin, in inhibiting CDK-6, a key enzyme involved in cell cycle regulation. The findings suggest that these inhibitors may offer a potential new approach to cancer treatment, but further research is needed to confirm their efficacy and safety.

Date :
  1. Date Completed 2020-05-20
  2. Date Revised 2020-05-20
Further Info :

Pubmed ID

31875784

DOI: Digital Object Identifier

10.2174/2589977511666191018180001

Related Literature

Article Analysis
・Effects of abemaciclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.